Once-daily blarcamesine was associated with minimal cognitive decline at 48 weeks, with changes comparable to those observed in prodromal aging.

Merck's CAPVAXIVE could cover approximately 78% of invasive pneumococcal disease cases in youth with chronic health conditions, vs other approved pneumococcal conjugate vaccines.

Sanofi's amlitelimab, dosed every 4 or 12 weeks, was superior to placebo in efficacy and skin clearance, with efficacy increasing throughout the treatment period.

Ada Stewart, MD, shares strategies for primary care physicians to reduce patient anxiety and improve comfort during cervical cancer screening exams.

Nor does receiving a diabetes diagnosis guarantee optimal management as just one-fifth of people treated for the disease reached glycemic control in 2023.

Nerandomilast, with a PDUFA date of Q4 2025, leads the potential breakthrough therapies, with inhaled treprostinil and admilparant advancing quickly behind.

Exact Sciences launches Cancerguard™, a groundbreaking blood test for early cancer detection, aiming to transform cancer screening and save lives.

Although overall risk was just slightly elevated, study authors recommend alternative imaging methods when appropriate for women of childbearing age.

Your daily dose of the clinical news you may have missed.

Family physician Teresa Lovins, MD, highlights key community mental health resources primary care clinicians should know to support patients in crisis.